Tiger Brokers

Sino Biopharma Unit Licenses Respiratory Drug Candidate to AstraZeneca in Up to $2.1 Billion Deal

MT Newswires Live
Jul 08

Sino Biopharmaceutical (HKG:1177) said subsidiary Chia Tai Tianqing Pharmaceutical Group signed an exclusive licensing agreement with AstraZeneca to develop, manufacture and commercialize its PDE3/4 inhibitor TQC3721 outside China.

TQC3721 is an inhaled drug candidate being developed for respiratory diseases, according to a Wednesday Hong Kong bourse filing.

Under the agreement, the group is eligible to receive an upfront payment of $200 million, as well as development, regulatory and sales milestone payments of up to $1.9 billion and tiered royalties based on annual net sales. AstraZeneca also obtained exclusive global rights to certain development programs in future.

The agreement is subject to customary closing conditions, including regulatory approvals.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10